Stem-cell hemotoxicity testing firm HemoGenix this week announced the launch of a 384-well plate version of its flagship HALO bioluminescent assay system for determining the effects of drugs on hematopoietic stem cells.

HemoGenix, which has traditionally garnered the majority of its revenues from contract hemotoxicity testing, hopes that the new higher throughput format will spur direct sales of its assay kits to pharmaceutical companies wishing to perform such testing in house, HemoGenix CEO Ivan Rich said this week.